Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) EBIT Margin (2016 - 2025)

Regenxbio (RGNX) has 12 years of EBIT Margin data on record, last reported at 189.99% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 5216.0% year-over-year to 189.99%; the TTM value through Dec 2025 reached 94.58%, up 18546.0%, while the annual FY2025 figure was 94.58%, 18546.0% up from the prior year.
  • EBIT Margin reached 189.99% in Q4 2025 per RGNX's latest filing, down from 176.27% in the prior quarter.
  • Across five years, EBIT Margin topped out at 670.14% in Q4 2023 and bottomed at 408.8% in Q1 2024.
  • Average EBIT Margin over 5 years is 180.88%, with a median of 235.12% recorded in 2021.
  • Peak YoY movement for EBIT Margin: skyrocketed 85445bps in 2023, then tumbled -91229bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 78.66% in 2021, then plummeted by -334bps to 184.31% in 2022, then soared by 464bps to 670.14% in 2023, then crashed by -136bps to 242.14% in 2024, then grew by 22bps to 189.99% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 189.99% in Q4 2025, 176.27% in Q3 2025, and 296.26% in Q2 2025.